# Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer

> **NCT01383668** · PHASE1 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Squamous Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sirolimus
- **DRUG:** gold sodium thiomalate
- **OTHER:** pharmacological study
- **GENETIC:** RNA analysis
- **GENETIC:** polymerase chain reaction

## Key facts

- **NCT ID:** NCT01383668
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-06
- **Primary completion:** 2013-02-08
- **Final completion:** 2013-02-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of access to study drug
- **Last updated:** 2020-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01383668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01383668, "Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01383668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*